Start Submission Become a Reviewer

Reading: Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation

Download

A- A+
Alt. Display

Review Article

Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation

Authors:

Mengqi Liu,

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou, Henan, CN
About Mengqi

MD

X close

Wenzhi Guo,

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou, Henan, CN
About Wenzhi

PhD

X close

Shuijun Zhang

Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Jianshe Road 1, Zhengzhou, Henan; Henan Key Laboratory of Digestive Organ Transplantation, Zhengzhou, Henan, CN
About Shuijun

PhD

X close

Abstract

Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ transplantation have extended patients’ lives, new or recurrent postsurgical malignancies have become an increasing threat to their long-term survival, especially in patients after liver transplantation due to hepatocellular carcinoma. The feasibility of immunotherapy treatment for such patients is still to be investigated.

How to Cite: Liu M, Guo W, Zhang S. Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. International Journal of Surgery: Oncology. 2017;2(11):e49. DOI: http://doi.org/10.1097/IJ9.0000000000000049
28
Views
8
Downloads
Published on 16 Nov 2017.
Peer Reviewed

Downloads

  • PDF (EN)